Rebif pivotal trial

560 patients RRMS 18-50 >= 2 exacerbations over 2 years, EDSS 0-5, no exacerbations for two months prior to study entry, 3 arms, placebo, 22 and 44 ug three times a week, two year followup. All four outcome measures, exacerbation rate, percentage of exacerbation free patients, MRI attack rate, and confirmed progression of disability were helped (confirmed progression was marginal). Higher dose suggestedmore efficacy but the data was not significantly robust on that point.